Caris Life Sciences, Inc. — Director's Dealing 2025

Jun 18, 2025

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Caris Life Sciences, Inc. (CAI)
CIK: 0002019410
Period of Report: 2025-06-17

Reporting Person: Brille Brian J (Director, See Remarks)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	500000	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option	$2.44	2028-01-14	Common Stock (2000000)		Direct
Stock Option	$8.00	2030-02-26	Common Stock (1000000)		Direct
Stock Option	$16.20	2032-08-11	Common Stock (437500)		Direct

Footnotes

F1: The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.

F2: The stock option is fully vested and exercisable.

F3: The stock option vests in five substantially equal annual installments beginning on August 11, 2022.